In this context, this study assessed the association between the CTLA4 c.-319C > T variant and CRC susceptibility, proposing its potential use as a biomarker for therapeutic response to anti-CTLA4 monoclonal antibody immunotherapy. The gene discussed is CTLA4; the disease is colorectal carcinoma.